Default company panoramic image
Logo

JB Therapeutics Inc

JBT is developing ajulemic acid (AJA) a nonpsychotropic synthetic THC derivative for the treatment of scleroderma & other fibrotic diseases

  • Stage Concept Only
  • Industry Biotechnology
  • Location Newton, MA, USA
  • Currency USD
  • Employees 5
  • Website jbtherapeutics.com

Company Summary

JBT is a clinical stage biopharmaceutical company developing a non-psychotropic synthetic derivative of THC, the active ingredient in marijuana. The first indication being pursued is scleroderma, a multibillion dollar orphan indication with high mortality and effective therapies. Due to prior investments in the clinical development of AJA for a different indication, JBT is able to reach a high ROI exit in 18 months with a $1.5M investment

Team

  • Default avatar
    Mark Tepper, Ph.D.
    President & CEO

  • Default avatar
    Jean Claude Becker, MD
    Chief Medical Officer

  • Default avatar
    Ed Monaghan, Ph.D
    VP, Pharmaceutical Development

  • Default avatar
    Garol Gloff, Ph.D.
    VP Regulatory Affairs

  • Default avatar
    Susan Wilson, DVM, Ph.D.
    VP Toxicology

Advisors

  • Default avatar
    Corp Counsel-Amy Mastrobattista, Roberto Weiner, Israel; IP Counsel-Louis Myers, LLA
    Lawyer
    Unconfirmed
    Default avatar
    Larry Nannis, Levine, Katz, Nannis and Solomon
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Boynton Angels|Founders|Vendors
    Unconfirmed